Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 29, 2015 08:01 ET | Source: TESARO, Inc.

TESARO Appoints Jeffrey H. Hanke, Ph.D., as Executive Vice President, Research & Development, and Chief Scientific Officer

WALTHAM, Mass., June 29, 2015 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq:TSRO), an oncology-focused biopharmaceutical company, today announced the appointment of Jeffrey H. Hanke, Ph.D., to the newly...
June 25, 2015 08:01 ET | Source: TESARO, Inc.

TESARO Announces Six Abstracts to be Presented at the 2015 Multinational Association of Supportive Care in Cancer Annual Meeting

WALTHAM, Mass., June 25, 2015 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq:TSRO), an oncology-focused biopharmaceutical company, today announced the presentation of six abstracts at the 2015 Multinational...
May 30, 2015 18:00 ET | Source: TESARO, Inc.

TESARO Announces Successful Completion of Rolapitant Bioequivalence Study

WALTHAM, Mass., May 30, 2015 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq:TSRO), an oncology-focused biopharmaceutical company, today announced the successful completion of the rolapitant bioequivalence...
May 30, 2015 14:00 ET | Source: TESARO, Inc.

TESARO and Merck to Collaborate on a Combination Study of Niraparib and KEYTRUDA(R) (Pembrolizumab)

WALTHAM, Mass. and KENILWORTH, N.J., May 30, 2015 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq:TSRO), an oncology-focused biopharmaceutical company, and Merck (NYSE:MRK), known as MSD outside the United...
May 20, 2015 08:01 ET | Source: TESARO, Inc.

TESARO Announces Webcast of Presentation at the Jefferies 2015 Global Healthcare Conference

WALTHAM, Mass., May 20, 2015 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq:TSRO), an oncology-focused biopharmaceutical company, announced today that Lonnie Moulder, CEO of TESARO, will present an overview...
May 14, 2015 09:37 ET | Source: TESARO, Inc.

TESARO Announces Election of Garry A. Nicholson to Board of Directors and Results of Annual Stockholder Meeting

WALTHAM, Mass., May 14, 2015 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq:TSRO), an oncology-focused biopharmaceutical company, today announced the results of its Annual Stockholder Meeting, which was...
May 13, 2015 17:30 ET | Source: TESARO, Inc.

TESARO Announces Seven Abstracts to Be Presented at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting

WALTHAM, Mass., May 13, 2015 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq:TSRO), an oncology-focused biopharmaceutical company, today announced the presentation of seven abstracts at the 2015 American...
April 30, 2015 16:02 ET | Source: TESARO, Inc.

TESARO Announces Completion of Targeted Enrollment in Phase 3 NOVA Trial and Initiation of the QUADRA Trial of Niraparib

Both the non-germline and germline BRCA mutation cohorts within NOVA are fully enrolled Phase 3 data from NOVA is expected in Q4 2015 Patients are now being treated within the QUADRA...
April 30, 2015 16:01 ET | Source: TESARO, Inc.

TESARO Announces First-Quarter 2015 Operating Results

Target enrollment completed for both cohorts of the niraparib Phase 3 NOVA trial; data expected in Q4 2015 QUADRA trial of niraparib initiated; initial data anticipated in early 2016 U.S....
April 23, 2015 08:01 ET | Source: TESARO, Inc.

TESARO Launches Campaign to Raise Awareness of Chemotherapy-Induced Nausea and Vomiting Among Patients With Cancer

WALTHAM, Mass., April 23, 2015 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq:TSRO), an oncology-focused biopharmaceutical company, today announced the launch of Ask About CINV, a campaign to raise...